TY - JOUR
T1 - Optimizing first line treatments for adults with OCD
AU - Nezgovorova, V.
AU - Reid, J.
AU - Fineberg, N. A.
AU - Hollander, E.
N1 - Funding Information:
Dr. Fineberg has received research funding from COST Action CA16207 and NIHR. She also has a leadership role as Chair, ECNP Review Board. Secretary, International college of obsessive compulsive spectrum disorders; as a Board member, Orchard advancing research in OCD; as a Chair, World Psychiatric Association scientific section for OCD and anxiety; as a Clinical lead, National OCD treatment service; and as an Expert adviser to the MHRA. She received support to attend meetings from British Association for Psychopharmacology, European College for Neuropsychopharmacology (ECNP), Royal College of Psychiatrists, International College for Neuropsychopharmacology, European COST Action, World Psychiatric Association, International Forum for Mood and Anxiety disorders and American College for Neuropsychopharmacology. Dr. Fineberg has contributed to writing of NICE OCD guidelines.
Funding Information:
Dr. Hollander has received research grants from GW Pharmaceuticals and Hoffman La-Roche. He has also received research funding from the Department of Defense and Food and Drug Administration Orphan Products Division. Dr. Hollander has contributed to writing of APA OCD treatment guidelines (2010).
Publisher Copyright:
© 2022
PY - 2022/5
Y1 - 2022/5
N2 - OCD is characterized by obsessions (recurrent, intrusive, unwanted thoughts, images or impulses and compulsions (repetitive behaviors or mental acts that the individual feels compelled to perform), which can manifest together or separately (Fineberg et al., 2020). NICE guidelines suggest that low intensity psychological treatments (including ERP) is the first line treatment for OCD, and that a “stepped care” treatment approach for OCD reserves combination treatment for adults with OCD with severe functional impairment, and for adults without an adequate response to: 1) treatment with an SSRI alone (12 weeks duration) or 2) CBT (including ERP) alone (NICE, 2005). Existing US treatment guidelines (APA guidelines) suggest that there are three first-line treatments for OCD (SSRI, CBT, SSRI+CBT) and recommends combined treatment for patients with an unsatisfactory response to monotherapy or for patients with severe OCD. Although, systematic review and meta-analysis of studies published in 1993–2014 suggest that combination treatment was not significantly better than CBT plus placebo (Ost et al., 2015), based on data from a recent systematic and meta-analysis which searched the two controlled trials registers maintained by the Cochrane Collaboration Common Mental Disorders group, the combination treatment approach is likely to be more effective than psychotherapeutic interventions alone, at least in severe obsessive-compulsive disorder (Skapinakis et al., 2016a). Based on data from Optimal treatment for OCD study conducted by Fineberg et al., (2018) combined treatment appeared to be the most effective especially when compared to CBT monotherapy, but SSRI monotherapy was found as the most cost effective. In this review we summarize available treatment recommendations.
AB - OCD is characterized by obsessions (recurrent, intrusive, unwanted thoughts, images or impulses and compulsions (repetitive behaviors or mental acts that the individual feels compelled to perform), which can manifest together or separately (Fineberg et al., 2020). NICE guidelines suggest that low intensity psychological treatments (including ERP) is the first line treatment for OCD, and that a “stepped care” treatment approach for OCD reserves combination treatment for adults with OCD with severe functional impairment, and for adults without an adequate response to: 1) treatment with an SSRI alone (12 weeks duration) or 2) CBT (including ERP) alone (NICE, 2005). Existing US treatment guidelines (APA guidelines) suggest that there are three first-line treatments for OCD (SSRI, CBT, SSRI+CBT) and recommends combined treatment for patients with an unsatisfactory response to monotherapy or for patients with severe OCD. Although, systematic review and meta-analysis of studies published in 1993–2014 suggest that combination treatment was not significantly better than CBT plus placebo (Ost et al., 2015), based on data from a recent systematic and meta-analysis which searched the two controlled trials registers maintained by the Cochrane Collaboration Common Mental Disorders group, the combination treatment approach is likely to be more effective than psychotherapeutic interventions alone, at least in severe obsessive-compulsive disorder (Skapinakis et al., 2016a). Based on data from Optimal treatment for OCD study conducted by Fineberg et al., (2018) combined treatment appeared to be the most effective especially when compared to CBT monotherapy, but SSRI monotherapy was found as the most cost effective. In this review we summarize available treatment recommendations.
KW - Adults
KW - First line treatments
KW - OCD
UR - http://www.scopus.com/inward/record.url?scp=85126667338&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126667338&partnerID=8YFLogxK
U2 - 10.1016/j.comppsych.2022.152305
DO - 10.1016/j.comppsych.2022.152305
M3 - Article
C2 - 35325671
AN - SCOPUS:85126667338
SN - 0010-440X
VL - 115
JO - Comprehensive Psychiatry
JF - Comprehensive Psychiatry
M1 - 152305
ER -